The sharp early decline on progression-free survival (PFS) curves for oral SERD monotherapy trials indicates that 40-50% of patients have resistance mechanisms beyond just an ESR1 mutation. This highlights the need for better patient selection for monotherapy versus combination approaches to overcome this multifaceted resistance.
The ideal candidate for single-agent oral SERD therapy after CDK4/6 inhibitor progression is well-defined. This patient profile includes having received over 12 months of benefit from the prior CDK4/6 inhibitor, being asymptomatic, and having disease progression confined to the bones, as this group derives significant benefit with lower toxicity.
PROTAC molecules, a new drug class, offer an advantage by completely degrading the estrogen receptor protein, regardless of whether estrogen is present. This mechanism helps overcome resistance from ESR1 mutations that make the receptor constantly active, independent of its natural ligand, estradiol.
Unlike the US, where Phase 2 trial data can support flexible use of drug combinations, European practice varies significantly. The UK strictly adheres to drug labels, while countries like Germany allow for more flexibility based on updated national guidelines and specific clinical contexts.
The SERENA-6 study represents a fundamental shift in oncology care. It tests the principle of intervening with therapy based on detecting an ESR1 mutation in ctDNA (molecular progression) *before* the patient shows signs of disease advancement on imaging scans (radiological progression), a new proactive treatment paradigm.
For patients with bone-predominant metastatic disease, repeating a tissue biopsy is often not feasible. A liquid biopsy (ctDNA analysis) is the preferred method as it is easier to perform and more likely to detect an ESR1 mutation compared to tissue-based NGS testing in this specific clinical scenario.